Researchers have discovered a terrifying new way for the new coronavirus to kill patients,media BGR reported. CoVID-19 patients died of serious complications that formed a jelly-like substance in the lungs. The accumulation of this substance can lead to respiratory failure and death. Researchers have found that a drug can slow the production of jelly-like substances and potentially save lives. They also found that steroids such as dexamisong can prevent the production of deadly hyaluronic acid “jelly”.
Most new crown patients recover without experiencing any serious complications. Some of them don’t even have any symptoms of COVID-19. But there are also many people who may have life-threatening complications. Age, gender, and a range of existing conditions make it harder for the immune system to fight the virus without the help of therapeutic agents. Not all COVID-19 treatments can save everyone now.
But COVID-19 research has advanced at an extremely rapid pace, and doctors who have been treating and studying patients with neo-coronary pneumonia have learned how to save more lives. The latest findings, which involve a serious complication that can lead to death, seem to confirm one of the most frightening complications of the new crown. Some people infected with COVID-19’s lungs fill up with fluid and then become “jelly”, making them unable to breathe. As respiratory failure worsens, affected patients will need breathing therapy, and many have died of this terrible condition.
Some researchers hypothesed earlier this year that a substance at viral levels called peptides has a direct effect on blood vessels and blood pressure. They say the compound causes water to seep out of blood vessels and fill the lungs. But that’s where things get more complicated – according to a September report inmedia.
Jacobson and his team believe COVID-19 may have another effect, complicating matters. The virus increases the production of hyalurinoic acid (HLA) and absorbs large amounts of liquid. When HLA interacts with fluid in the lungs, the end result is a hydrogel that makes breathing more difficult. At this point, it’s likely that you won’t even be able to help with the ventilator. “It reaches a point where no matter how much oxygen you pump, it doesn’t matter because the lungs are full of this hydrogel,” Jacobson said. “The lungs become like a water polo.”
The following diagram in Jacobson’s paper further explains this process.
A new study from the University of Mayo describes the same phenomenon. The researchers found liquid gels in the lungs of patients who died of complications from COVID-19. This time, researchers have come up with a treatment that could prevent the chemical process that causes the deadly lung jelly to form.
“There are already treatments that can slow the body down to produce this ‘jelly’, or break down this ‘jelly’ with an enzyme. Our findings may also explain why cosmos appears to have an effect on COVID-19,” Urban Hellman, a researcher at the University of Yumo, said in a statement.
Scientists have discovered transparent liquid ‘jelly’ in the lungs of deceased COVID-19 patients, making them look like the lungs of a drowning person. They say the jelly is made up of “hyaluracin, a polysaccharide of glycamine polysaccharides.” Hyaluric acid is also mentioned in the diagram above.
Hyaluric acid is a common substance in the human body, it is involved in wound healing and other functions. But when it forms in the lungs of patients with COVID-19, it can be fatal. “It is this process that causes the patient to need ventilator care and, in the worst case, to die of respiratory failure in the alcups of the lungs of COVID-19 patients,” the researchers said.
The team of scientists believes a drug called Hymecromone could be used to slow the production of hyaluracid acid in diseases such as gallbladder attacks. They also explained that cortisol can reduce the production of hyaluronic acid, which is why dexamisunds and other steroids can improve symptoms and save lives in patients experiencing severe COVID-19 complications.
The study from the University of Mayo is likely to be one of the biggest breakthroughs so far this year, as it could lead to new treatments that could save more lives. But as with other studies, more research is needed to support these findings. Clinical trials of hydroxymethyl beanin and similar drugs are also needed before the drug can be used to fight COVID-19. The full study is available in the Journal of Biochemistry.